nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA6—saliva—conduct disorder	0.122	0.226	CbGeAlD
Nilotinib—EPHB2—brain—conduct disorder	0.021	0.0389	CbGeAlD
Nilotinib—EPHA8—brain—conduct disorder	0.0201	0.0373	CbGeAlD
Nilotinib—MAPK11—brain—conduct disorder	0.0187	0.0347	CbGeAlD
Nilotinib—CDC42BPB—brain—conduct disorder	0.0186	0.0344	CbGeAlD
Nilotinib—EPHA3—brain—conduct disorder	0.0176	0.0326	CbGeAlD
Nilotinib—MAPK8—brain—conduct disorder	0.0168	0.0311	CbGeAlD
Nilotinib—EPHA6—brain—conduct disorder	0.0168	0.0311	CbGeAlD
Nilotinib—LYN—brain—conduct disorder	0.0155	0.0287	CbGeAlD
Nilotinib—MAP4K1—brain—conduct disorder	0.0153	0.0283	CbGeAlD
Nilotinib—TIE1—brain—conduct disorder	0.0146	0.027	CbGeAlD
Nilotinib—BRAF—brain—conduct disorder	0.014	0.0259	CbGeAlD
Nilotinib—EPHB3—brain—conduct disorder	0.0138	0.0256	CbGeAlD
Nilotinib—HCK—brain—conduct disorder	0.0127	0.0236	CbGeAlD
Nilotinib—ABL2—brain—conduct disorder	0.0126	0.0234	CbGeAlD
Nilotinib—CA7—brain—conduct disorder	0.0125	0.0231	CbGeAlD
Nilotinib—EPHA4—brain—conduct disorder	0.0116	0.0214	CbGeAlD
Nilotinib—CA3—brain—conduct disorder	0.0114	0.0212	CbGeAlD
Nilotinib—MAPK14—brain—conduct disorder	0.0107	0.0198	CbGeAlD
Nilotinib—FGR—brain—conduct disorder	0.0106	0.0197	CbGeAlD
Nilotinib—CA14—brain—conduct disorder	0.0104	0.0192	CbGeAlD
Nilotinib—EPHB4—brain—conduct disorder	0.0101	0.0187	CbGeAlD
Nilotinib—EPHA2—brain—conduct disorder	0.00992	0.0184	CbGeAlD
Nilotinib—TEK—brain—conduct disorder	0.00967	0.0179	CbGeAlD
Nilotinib—EPHB6—brain—conduct disorder	0.00924	0.0171	CbGeAlD
Nilotinib—PDGFRA—brain—conduct disorder	0.00876	0.0162	CbGeAlD
Nilotinib—CA12—brain—conduct disorder	0.00809	0.015	CbGeAlD
Nilotinib—MAP2K5—brain—conduct disorder	0.00791	0.0146	CbGeAlD
Nilotinib—CSF1R—brain—conduct disorder	0.00772	0.0143	CbGeAlD
Nilotinib—KIT—brain—conduct disorder	0.00701	0.013	CbGeAlD
Nilotinib—PDGFRB—brain—conduct disorder	0.00684	0.0127	CbGeAlD
Nilotinib—CA1—brain—conduct disorder	0.00641	0.0119	CbGeAlD
Nilotinib—ABL1—brain—conduct disorder	0.0061	0.0113	CbGeAlD
Nilotinib—CA4—brain—conduct disorder	0.00501	0.00928	CbGeAlD
Nilotinib—CA2—brain—conduct disorder	0.00415	0.00769	CbGeAlD
Nilotinib—CYP2C8—brain—conduct disorder	0.00396	0.00733	CbGeAlD
Nilotinib—ABCG2—brain—conduct disorder	0.00385	0.00712	CbGeAlD
Nilotinib—CYP2B6—brain—conduct disorder	0.00355	0.00657	CbGeAlD
Nilotinib—CYP2D6—brain—conduct disorder	0.00264	0.00488	CbGeAlD
Nilotinib—ABCB1—brain—conduct disorder	0.0019	0.00351	CbGeAlD
Nilotinib—LCK—Notch Signaling Pathway—EP300—conduct disorder	0.00115	0.0025	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—POLR3A—conduct disorder	0.00114	0.00248	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—POLR3A—conduct disorder	0.00114	0.00247	CbGpPWpGaD
Nilotinib—ABL1—p73 transcription factor network—EP300—conduct disorder	0.00113	0.00247	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.00113	0.00246	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—POLR3A—conduct disorder	0.00111	0.00241	CbGpPWpGaD
Nilotinib—BLK—Immune System—POLR3A—conduct disorder	0.00111	0.00241	CbGpPWpGaD
Nilotinib—FGR—Immune System—POLR3A—conduct disorder	0.00111	0.0024	CbGpPWpGaD
Nilotinib—CA3—Metabolism—COMT—conduct disorder	0.00109	0.00238	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—WASF1—conduct disorder	0.00109	0.00237	CbGpPWpGaD
Nilotinib—CA3—Metabolism—MAOA—conduct disorder	0.00109	0.00236	CbGpPWpGaD
Nilotinib—KIT—Immune System—MB21D1—conduct disorder	0.00109	0.00236	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—POLR3A—conduct disorder	0.00108	0.00235	CbGpPWpGaD
Nilotinib—MAPK14—p73 transcription factor network—EP300—conduct disorder	0.00108	0.00235	CbGpPWpGaD
Nilotinib—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00108	0.00234	CbGpPWpGaD
Nilotinib—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00107	0.00232	CbGpPWpGaD
Nilotinib—CA4—Metabolism—CGA—conduct disorder	0.00105	0.00228	CbGpPWpGaD
Nilotinib—MAPK14—Glucocorticoid receptor regulatory network—EP300—conduct disorder	0.00105	0.00228	CbGpPWpGaD
Nilotinib—ABCG2—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00104	0.00227	CbGpPWpGaD
Nilotinib—HCK—Immune System—WASF1—conduct disorder	0.00103	0.00224	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—MB21D1—conduct disorder	0.00103	0.00223	CbGpPWpGaD
Nilotinib—CA2—Metabolism—CGA—conduct disorder	0.00101	0.00219	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—WASF1—conduct disorder	0.000982	0.00213	CbGpPWpGaD
Nilotinib—CA1—Metabolism—CGA—conduct disorder	0.000966	0.0021	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—WASF1—conduct disorder	0.000961	0.00209	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—WASF1—conduct disorder	0.000957	0.00208	CbGpPWpGaD
Nilotinib—MAPK8—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000938	0.00204	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—POLR3A—conduct disorder	0.000936	0.00203	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—WASF1—conduct disorder	0.000934	0.00203	CbGpPWpGaD
Nilotinib—BLK—Immune System—WASF1—conduct disorder	0.000934	0.00203	CbGpPWpGaD
Nilotinib—FGR—Immune System—WASF1—conduct disorder	0.00093	0.00202	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MB21D1—conduct disorder	0.000926	0.00201	CbGpPWpGaD
Nilotinib—ABL1—Cell Cycle—EP300—conduct disorder	0.000925	0.00201	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—WASF1—conduct disorder	0.000911	0.00198	CbGpPWpGaD
Nilotinib—LYN—Immune System—MB21D1—conduct disorder	0.000906	0.00197	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MB21D1—conduct disorder	0.000902	0.00196	CbGpPWpGaD
Nilotinib—MAPK8—Circadian rythm related genes—EP300—conduct disorder	0.0009	0.00196	CbGpPWpGaD
Nilotinib—BRAF—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000893	0.00194	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—POLR3A—conduct disorder	0.000884	0.00192	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—POLR3A—conduct disorder	0.000879	0.00191	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MB21D1—conduct disorder	0.000859	0.00187	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000859	0.00187	CbGpPWpGaD
Nilotinib—CA9—Metabolism—CGA—conduct disorder	0.000849	0.00184	CbGpPWpGaD
Nilotinib—EPHB3—Developmental Biology—EP300—conduct disorder	0.000832	0.00181	CbGpPWpGaD
Nilotinib—CYP2B6—Biological oxidations—COMT—conduct disorder	0.00083	0.0018	CbGpPWpGaD
Nilotinib—CYP2B6—Biological oxidations—MAOA—conduct disorder	0.000824	0.00179	CbGpPWpGaD
Nilotinib—CYP2B6—Metapathway biotransformation—COMT—conduct disorder	0.000819	0.00178	CbGpPWpGaD
Nilotinib—KIT—Immune System—POLR3A—conduct disorder	0.000797	0.00173	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—WASF1—conduct disorder	0.000788	0.00171	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—POLR3A—conduct disorder	0.000754	0.00164	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CGA—conduct disorder	0.000753	0.00164	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—WASF1—conduct disorder	0.000744	0.00162	CbGpPWpGaD
Nilotinib—LCK—Immune System—MB21D1—conduct disorder	0.000743	0.00161	CbGpPWpGaD
Nilotinib—EPHA3—Developmental Biology—EP300—conduct disorder	0.000741	0.00161	CbGpPWpGaD
Nilotinib—ABL2—Developmental Biology—EP300—conduct disorder	0.000741	0.00161	CbGpPWpGaD
Nilotinib—ABL1—Factors involved in megakaryocyte development and platelet production—EP300—conduct disorder	0.000735	0.0016	CbGpPWpGaD
Nilotinib—MAPK8—Cellular responses to stress—EP300—conduct disorder	0.000724	0.00157	CbGpPWpGaD
Nilotinib—MAPK14—TGF-beta Signaling Pathway—EP300—conduct disorder	0.000716	0.00156	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CGA—conduct disorder	0.000716	0.00156	CbGpPWpGaD
Nilotinib—EPHA8—Developmental Biology—EP300—conduct disorder	0.000715	0.00155	CbGpPWpGaD
Nilotinib—EPHB4—Developmental Biology—EP300—conduct disorder	0.000707	0.00154	CbGpPWpGaD
Nilotinib—EPHA4—Developmental Biology—EP300—conduct disorder	0.000707	0.00154	CbGpPWpGaD
Nilotinib—CA14—Metabolism—COMT—conduct disorder	0.000706	0.00153	CbGpPWpGaD
Nilotinib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000705	0.00153	CbGpPWpGaD
Nilotinib—CYP2C8—Biological oxidations—COMT—conduct disorder	0.000703	0.00153	CbGpPWpGaD
Nilotinib—CA14—Metabolism—MAOA—conduct disorder	0.000701	0.00152	CbGpPWpGaD
Nilotinib—CYP2C8—Biological oxidations—MAOA—conduct disorder	0.000698	0.00152	CbGpPWpGaD
Nilotinib—CYP2C8—Metapathway biotransformation—COMT—conduct disorder	0.000693	0.00151	CbGpPWpGaD
Nilotinib—CA6—Metabolism—COMT—conduct disorder	0.000688	0.00149	CbGpPWpGaD
Nilotinib—EPHB2—Developmental Biology—EP300—conduct disorder	0.000685	0.00149	CbGpPWpGaD
Nilotinib—CA6—Metabolism—MAOA—conduct disorder	0.000683	0.00148	CbGpPWpGaD
Nilotinib—CA9—Cellular responses to stress—EP300—conduct disorder	0.000682	0.00148	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—POLR3A—conduct disorder	0.00068	0.00148	CbGpPWpGaD
Nilotinib—ABL1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000676	0.00147	CbGpPWpGaD
Nilotinib—KIT—Immune System—WASF1—conduct disorder	0.000671	0.00146	CbGpPWpGaD
Nilotinib—LYN—Immune System—POLR3A—conduct disorder	0.000665	0.00145	CbGpPWpGaD
Nilotinib—TEK—Hemostasis—EP300—conduct disorder	0.000665	0.00145	CbGpPWpGaD
Nilotinib—EPHB6—Developmental Biology—EP300—conduct disorder	0.000665	0.00144	CbGpPWpGaD
Nilotinib—ABL1—Immune System—POLR3A—conduct disorder	0.000662	0.00144	CbGpPWpGaD
Nilotinib—CA7—Metabolism—COMT—conduct disorder	0.000642	0.00139	CbGpPWpGaD
Nilotinib—PDGFRA—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000638	0.00139	CbGpPWpGaD
Nilotinib—CA7—Metabolism—MAOA—conduct disorder	0.000637	0.00139	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—WASF1—conduct disorder	0.000635	0.00138	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—POLR3A—conduct disorder	0.000631	0.00137	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—POLR3A—conduct disorder	0.000627	0.00136	CbGpPWpGaD
Nilotinib—EPHA6—Developmental Biology—EP300—conduct disorder	0.000625	0.00136	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—WASF1—conduct disorder	0.000604	0.00131	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CGA—conduct disorder	0.0006	0.0013	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000598	0.0013	CbGpPWpGaD
Nilotinib—CA12—Metabolism—COMT—conduct disorder	0.000595	0.00129	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CGA—conduct disorder	0.000594	0.00129	CbGpPWpGaD
Nilotinib—CA12—Metabolism—MAOA—conduct disorder	0.00059	0.00128	CbGpPWpGaD
Nilotinib—CYP2D6—Biological oxidations—COMT—conduct disorder	0.000577	0.00125	CbGpPWpGaD
Nilotinib—MAPK11—Cellular responses to stress—EP300—conduct disorder	0.000577	0.00125	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—EP300—conduct disorder	0.000576	0.00125	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—WASF1—conduct disorder	0.000574	0.00125	CbGpPWpGaD
Nilotinib—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.000573	0.00124	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—WASF1—conduct disorder	0.000572	0.00124	CbGpPWpGaD
Nilotinib—CYP2C9—Biological oxidations—COMT—conduct disorder	0.000572	0.00124	CbGpPWpGaD
Nilotinib—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000569	0.00124	CbGpPWpGaD
Nilotinib—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.000568	0.00123	CbGpPWpGaD
Nilotinib—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000565	0.00123	CbGpPWpGaD
Nilotinib—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.000564	0.00123	CbGpPWpGaD
Nilotinib—LYN—Immune System—WASF1—conduct disorder	0.00056	0.00122	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00056	0.00122	CbGpPWpGaD
Nilotinib—ABL1—Immune System—WASF1—conduct disorder	0.000557	0.00121	CbGpPWpGaD
Nilotinib—LCK—Immune System—POLR3A—conduct disorder	0.000545	0.00119	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CGA—conduct disorder	0.000541	0.00118	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000533	0.00116	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—WASF1—conduct disorder	0.000531	0.00115	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CGA—conduct disorder	0.000512	0.00111	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CGA—conduct disorder	0.000506	0.0011	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000487	0.00106	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—WASF1—conduct disorder	0.000481	0.00105	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—WASF1—conduct disorder	0.000476	0.00104	CbGpPWpGaD
Nilotinib—CA4—Metabolism—COMT—conduct disorder	0.000474	0.00103	CbGpPWpGaD
Nilotinib—CA4—Metabolism—MAOA—conduct disorder	0.000471	0.00102	CbGpPWpGaD
Nilotinib—CA3—Metabolism—EP300—conduct disorder	0.00047	0.00102	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000464	0.00101	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CGA—conduct disorder	0.000461	0.001	CbGpPWpGaD
Nilotinib—LCK—Immune System—WASF1—conduct disorder	0.000459	0.000998	CbGpPWpGaD
Nilotinib—CA2—Metabolism—COMT—conduct disorder	0.000455	0.000988	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CGA—conduct disorder	0.000452	0.000982	CbGpPWpGaD
Nilotinib—CA2—Metabolism—MAOA—conduct disorder	0.000451	0.000981	CbGpPWpGaD
Nilotinib—CA1—Metabolism—COMT—conduct disorder	0.000436	0.000947	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—WASF1—conduct disorder	0.000434	0.000942	CbGpPWpGaD
Nilotinib—CA1—Metabolism—MAOA—conduct disorder	0.000433	0.000941	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CGA—conduct disorder	0.000429	0.000932	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—EP300—conduct disorder	0.000429	0.000931	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CGA—conduct disorder	0.000428	0.000931	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—EP300—conduct disorder	0.000427	0.000929	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—DRD4—conduct disorder	0.000422	0.000917	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—EP300—conduct disorder	0.000412	0.000894	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—WASF1—conduct disorder	0.00041	0.000892	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—DRD4—conduct disorder	0.000401	0.000871	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—EP300—conduct disorder	0.000387	0.000841	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—EP300—conduct disorder	0.000386	0.000839	CbGpPWpGaD
Nilotinib—CA9—Metabolism—COMT—conduct disorder	0.000383	0.000833	CbGpPWpGaD
Nilotinib—CA9—Metabolism—MAOA—conduct disorder	0.00038	0.000827	CbGpPWpGaD
Nilotinib—CYP3A4—Biological oxidations—COMT—conduct disorder	0.000377	0.00082	CbGpPWpGaD
Nilotinib—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.000375	0.000814	CbGpPWpGaD
Nilotinib—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.000372	0.000808	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CGA—conduct disorder	0.00037	0.000805	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—WASF1—conduct disorder	0.00037	0.000804	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—WASF1—conduct disorder	0.000362	0.000787	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—EP300—conduct disorder	0.000349	0.000759	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—WASF1—conduct disorder	0.000343	0.000746	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—DRD4—conduct disorder	0.000336	0.00073	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—DRD4—conduct disorder	0.000333	0.000723	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CGA—conduct disorder	0.000314	0.000683	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—EP300—conduct disorder	0.000308	0.00067	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—DRD4—conduct disorder	0.000303	0.000659	CbGpPWpGaD
Nilotinib—CA14—Metabolism—EP300—conduct disorder	0.000303	0.000658	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—WASF1—conduct disorder	0.000297	0.000645	CbGpPWpGaD
Nilotinib—CA6—Metabolism—EP300—conduct disorder	0.000295	0.000641	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—DRD4—conduct disorder	0.000287	0.000623	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—EP300—conduct disorder	0.000278	0.000604	CbGpPWpGaD
Nilotinib—CA7—Metabolism—EP300—conduct disorder	0.000275	0.000598	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HTR2A—conduct disorder	0.000275	0.000598	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CGA—conduct disorder	0.000266	0.000579	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—EP300—conduct disorder	0.000263	0.000572	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—EP300—conduct disorder	0.000263	0.000571	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—EP300—conduct disorder	0.000262	0.000569	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HTR2A—conduct disorder	0.000262	0.000569	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—DRD4—conduct disorder	0.000258	0.000562	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—EP300—conduct disorder	0.000258	0.000561	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—EP300—conduct disorder	0.000257	0.000558	CbGpPWpGaD
Nilotinib—CA12—Metabolism—EP300—conduct disorder	0.000255	0.000554	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—DRD4—conduct disorder	0.000253	0.00055	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—EP300—conduct disorder	0.000249	0.000542	CbGpPWpGaD
Nilotinib—HCK—Immune System—EP300—conduct disorder	0.000249	0.000541	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—EP300—conduct disorder	0.000245	0.000531	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000241	0.000525	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—DRD4—conduct disorder	0.00024	0.000521	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—EP300—conduct disorder	0.000237	0.000515	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EP300—conduct disorder	0.000232	0.000505	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CGA—conduct disorder	0.000232	0.000504	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EP300—conduct disorder	0.000231	0.000502	CbGpPWpGaD
Nilotinib—HCK—Disease—EP300—conduct disorder	0.00023	0.000499	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—COMT—conduct disorder	0.000228	0.000496	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MAOA—conduct disorder	0.000227	0.000493	CbGpPWpGaD
Nilotinib—BLK—Immune System—EP300—conduct disorder	0.000225	0.00049	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EP300—conduct disorder	0.000225	0.00049	CbGpPWpGaD
Nilotinib—FGR—Immune System—EP300—conduct disorder	0.000225	0.000488	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EP300—conduct disorder	0.00022	0.000478	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HTR2A—conduct disorder	0.000219	0.000476	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CGA—conduct disorder	0.000219	0.000475	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HTR2A—conduct disorder	0.000217	0.000472	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CGA—conduct disorder	0.000217	0.000471	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—EP300—conduct disorder	0.000211	0.00046	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DRD4—conduct disorder	0.000207	0.000451	CbGpPWpGaD
Nilotinib—CA4—Metabolism—EP300—conduct disorder	0.000203	0.000442	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HTR2A—conduct disorder	0.000198	0.00043	CbGpPWpGaD
Nilotinib—CA2—Metabolism—EP300—conduct disorder	0.000195	0.000424	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—COMT—conduct disorder	0.000194	0.000421	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MAOA—conduct disorder	0.000192	0.000418	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EP300—conduct disorder	0.00019	0.000414	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HTR2A—conduct disorder	0.000187	0.000407	CbGpPWpGaD
Nilotinib—CA1—Metabolism—EP300—conduct disorder	0.000187	0.000406	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EP300—conduct disorder	0.00018	0.00039	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HTR2A—conduct disorder	0.000169	0.000366	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HTR2A—conduct disorder	0.000165	0.000359	CbGpPWpGaD
Nilotinib—BRAF—Disease—EP300—conduct disorder	0.000164	0.000357	CbGpPWpGaD
Nilotinib—CA9—Metabolism—EP300—conduct disorder	0.000164	0.000357	CbGpPWpGaD
Nilotinib—KIT—Immune System—EP300—conduct disorder	0.000162	0.000352	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HTR2A—conduct disorder	0.000156	0.00034	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EP300—conduct disorder	0.000153	0.000333	CbGpPWpGaD
Nilotinib—KIT—Disease—EP300—conduct disorder	0.00015	0.000325	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EP300—conduct disorder	0.000146	0.000317	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CGA—conduct disorder	0.000143	0.000311	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—COMT—conduct disorder	0.000142	0.000309	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EP300—conduct disorder	0.000142	0.000308	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MAOA—conduct disorder	0.000141	0.000306	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EP300—conduct disorder	0.000139	0.000301	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EP300—conduct disorder	0.000138	0.0003	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HTR2A—conduct disorder	0.000135	0.000294	CbGpPWpGaD
Nilotinib—LYN—Immune System—EP300—conduct disorder	0.000135	0.000294	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EP300—conduct disorder	0.000135	0.000293	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EP300—conduct disorder	0.000128	0.000279	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EP300—conduct disorder	0.000128	0.000277	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—COMT—conduct disorder	0.00012	0.000261	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MAOA—conduct disorder	0.000119	0.000259	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EP300—conduct disorder	0.000116	0.000252	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000116	0.000251	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EP300—conduct disorder	0.000115	0.00025	CbGpPWpGaD
Nilotinib—LCK—Immune System—EP300—conduct disorder	0.000111	0.000241	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EP300—conduct disorder	0.000105	0.000228	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—COMT—conduct disorder	0.000105	0.000228	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MAOA—conduct disorder	0.000104	0.000226	CbGpPWpGaD
Nilotinib—LCK—Disease—EP300—conduct disorder	0.000102	0.000222	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EP300—conduct disorder	9.91e-05	0.000215	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—COMT—conduct disorder	9.87e-05	0.000214	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MAOA—conduct disorder	9.8e-05	0.000213	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—EP300—conduct disorder	9.79e-05	0.000213	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—COMT—conduct disorder	9.78e-05	0.000213	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MAOA—conduct disorder	9.71e-05	0.000211	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	9.42e-05	0.000205	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—conduct disorder	8.93e-05	0.000194	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—conduct disorder	8.75e-05	0.00019	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—conduct disorder	8.3e-05	0.00018	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—conduct disorder	8.29e-05	0.00018	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—conduct disorder	7.17e-05	0.000156	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—COMT—conduct disorder	6.45e-05	0.00014	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MAOA—conduct disorder	6.41e-05	0.000139	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—conduct disorder	6.09e-05	0.000132	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—conduct disorder	5.15e-05	0.000112	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—conduct disorder	4.49e-05	9.76e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—conduct disorder	4.23e-05	9.2e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—conduct disorder	4.19e-05	9.12e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—conduct disorder	2.77e-05	6.01e-05	CbGpPWpGaD
